Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $24.62 in the last session, up 0.33% from day before closing price of $24.54. In other words, the price has increased by $0.33 from its previous closing price. On the day, 0.69 million shares were traded. CLDX stock price reached its highest trading level at $24.97 during the session, while it also had its lowest trading level at $24.07.
Ratios:
We take a closer look at CLDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 24.27 and its Current Ratio is at 24.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1633394304 and an Enterprise Value of 880483072. For the stock, the TTM Price-to-Sale (P/S) ratio is 163.67 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 88.26 whereas that against EBITDA is -5.147.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.60, which has changed by -0.30096537 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.17. The 50-Day Moving Average of the stock is -3.70%, while the 200-Day Moving Average is calculated to be -25.99%.
Shares Statistics:
According to the various share statistics, CLDX traded on average about 1.07M shares per day over the past 3-months and 903700 shares per day over the past 10 days. A total of 66.34M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.48% of the company’s shares, while institutions hold 105.03% stake in the company. Shares short for CLDX as of 1736899200 were 8480235 with a Short Ratio of 7.95, compared to 1734048000 on 7308344. Therefore, it implies a Short% of Shares Outstanding of 8480235 and a Short% of Float of 14.78.
